Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 6, Pages 1383
Publisher
MDPI AG
Online
2021-03-18
DOI
10.3390/cancers13061383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
- (2020) Cindy Patinote et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
- (2020) Shyambabu Chaurasiya et al. Cancers
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
- (2019) Steven S Raman et al. Immunotherapy
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study
- (2018) H Gogas et al. ANNALS OF ONCOLOGY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Oncolytic virus therapy: A new era of cancer treatment at dawn
- (2016) Hiroshi Fukuhara et al. CANCER SCIENCE
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
- (2016) Kevin Harrington et al. OncoTargets and Therapy
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
- (2015) F. J. Kohlhapp et al. CLINICAL CANCER RESEARCH
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
- (2014) John F. Thompson et al. ANNALS OF SURGICAL ONCOLOGY
- In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
- (2014) Rebecca L. Read et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma
- (2014) Merrick I. Ross JOURNAL OF SURGICAL ONCOLOGY
- Topical pharmacotherapy for skin cancer
- (2014) Giuseppe Micali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
- (2014) Christine E Engeland et al. MOLECULAR THERAPY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Treatment of metastatic melanoma with electrochemotherapy
- (2013) Luca G. Campana et al. JOURNAL OF SURGICAL ONCOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- High response rate after intratumoral treatment with interleukin-2
- (2010) Benjamin Weide et al. CANCER
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Contrasting roles for all-trans retinoic acid in TGF-β–mediated induction ofFoxp3andIl10genes in developing regulatory T cells
- (2009) Craig L. Maynard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
- (2008) Z. Sheng Guo et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- NK cells and cancer immunosurveillance
- (2008) I Waldhauer et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search